Telisotuzumab Vedotin Clinical Trials

3 actively recruiting trials across 3 locations

No change since May 2026

Also known as: ABBV 399, ABBV-399, ABT 399, ABT-399, ABT-700-VCMMAE +2 more

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

AbbVie2
Jonsson Comprehensive Cancer Center1

Indications

Lung Cancer3
Cancer3
Non Small Cell Lung Cancer2
Lung Non-Small Cell Carcinoma1

Birmingham, Alabama1 trial

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University of Alabama at Birmingham - Main /ID# 247074

Phase 3

Chandler, Arizona1 trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Ironwood Cancer & Research Center /ID# 276370

Phase 2

Los Angeles, California1 trial

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.